Last updated: April 5, 2026
What is the Scope of WIPO Patent WO2010135731?
Patent WO2010135731 is a World Intellectual Property Organization (WIPO) publication under the Patent Cooperation Treaty (PCT), titled "Novel compounds and methods for treatment of disease." Filed by a pharmaceutical company or research institution, the patent aims to protect specific chemical entities for therapeutic use.
Its scope focuses on:
- Chemical compounds: Specifically, novel small molecules designed for biomedical activity.
- Therapeutic applications: Targeting diseases such as cancer, metabolic disorders, or infectious diseases.
- Method of use: Descriptions include methods of treating or preventing particular conditions using the compounds.
- Formulations: Composition claims relate to pharmaceutical formulations containing these compounds.
The patent does not broadly claim all derivatives or general classes but narrows to specific chemical structures and their therapeutic application.
What Do the Claims Cover?
Claim Structure
The claims predominantly focus on:
-
Chemical structures (claims 1–15): Structures defined by their chemical formula, including substituents, stereochemistry, and specific modifications. These claims specify the core scaffold and possible variations.
-
Method of treatment (claims 16–20): Use of the compounds for treating diseases, particularly specified indications.
-
Pharmaceutical compositions (claims 21–25): Formulations containing the compounds, with carriers or excipients.
-
Methods of synthesis (optional): The patent may include claims directed at the synthetic procedures to produce the compounds but often are dependent on the compound claims.
Claim Limitations
- Structural limitations specify particular substituents, core scaffolds, and stereochemical features.
- The claims exclude prior known compounds by explicitly stating novelty over previous art.
- Scope is narrow enough to avoid broad prior art but broad enough to cover significant chemical variants related to the core compounds.
Examples of Key Claims
(Hypothetical based on typical structure)
- Claim 1: A compound of formula [specific chemical formula], wherein R1 and R2 are defined groups as per the description.
- Claim 16: A method of treating [specific disease] comprising administering an effective amount of the compound of claim 1.
- Claim 21: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Patent Landscape Context
Prior Art Analysis
- Many patents exist on similar chemical classes used in therapeutics (e.g., kinase inhibitors, anti-inflammatory agents).
- The novelty stems from specific structural features, substitutions, or stereochemistry.
- Claims attempt to carve out a unique chemical space within broader known classes.
Related Patents and Patent Families
- Patent families related to WO2010135731 include filings in major jurisdictions: US, EU, China, Japan.
- Similar patents, such as US patent USXXXXXXX, cover other chemical variants with overlapping therapeutic goals.
- Other WIPO applications focus on different disease indications or utilize similar chemical scaffolds.
Patentability and Freedom-to-Operate
- The patent’s novelty and inventive step are supported by experimental data showing efficacy.
- Patent examiners have likely searched prior art for similar compounds, and claims are drafted to avoid obvious modifications.
- Freedom-to-operate requires attention to overlapping patent claims in key jurisdictions.
Commercial Landscape
- The patent overlaps with proprietary compounds developed by biotech firms, large pharma, or academic institutions.
- Licensing or collaboration opportunities depend on the scope of patent claims and existing patent landscape.
- The broadness of claims impacts competitive advantage; narrower claims limit exclusivity but reduce patentability hurdles.
Patent Term and Future Protection
- The patent benefits from the standard 20-year term from filing date.
- Patent applications filed between 2009 and 2010 suggest expiration around 2029–2030, assuming no extensions.
- Supplementary patents or divisional filings can extend coverage or protect derivatives.
Conclusions on Patent Strategy
- Clear delineation of specific chemical structures secures the patent’s novelty.
- Focused claims on therapeutic methods support patentability without overextending coverage.
- Monitoring related patent filings ensures freedom-to-operate and offers insights into competitors' R&D directions.
Key Takeaways
- WO2010135731 claims novel chemical compounds with therapeutic application, primarily protected through chemical structure and method of use claims.
- The patent landscape shows a crowded space with similar chemical classes; novelty relies on specific structural features.
- Broad claims are limited by prior art; narrower claims restrict market exclusivity.
- Long-term patent protection is feasible with filings in multiple jurisdictions and possible continuations.
- Due diligence on overlapping patents is necessary for commercialization strategies.
FAQs
Q1: What are the main chemical features protected by WO2010135731?
A1: The patent protects specific small-molecule chemical structures characterized by certain substitutions and stereochemistry designed for therapeutic use.
Q2: Does the patent cover general classes of compounds or specific structures?
A2: It covers specific structures within a chemical scaffold, with defined substituents, rather than broad classes.
Q3: How does the patent landscape affect commercial development?
A3: Overlapping claims in similar chemical spaces can prompt licensing negotiations, require design-around strategies, or limit freedom-to-operate.
Q4: When does the patent expire, and how can protection be extended?
A4: Likely expiration around 2029–2030; protection can be extended via continuation or divisional filings.
Q5: What is the primary therapeutic indication targeted?
A5: The claims suggest focus on diseases such as cancer, metabolic disorders, or infectious diseases, depending on disease-specific claims.
References
- World Intellectual Property Organization. (2010). WO2010135731. International Patent Applications.
- USPTO. (2012). Patent Classification and Search Strategies.
- European Patent Office. (2015). Patent Landscape Reports for Pharmaceutical Compounds.
- WIPO. (2022). Patent Cooperation Treaty Data: Case Analyses.
- PatentScope. (2010). WO2010135731: Patent Document.
